Results 201 to 210 of about 384,012 (260)

Transthyretin amyloid cardiomyopathy

Medicina Clínica (English Edition), 2021
Transthyretin (TTR) cardiac amyloidosis is a severe, progressive, infiltrative disease caused by the deposition of TTR at cardiac level. It may be due to a genetic alteration in its hereditary form (ATTRv) or as a consequence of an age-related degenerative process (ATTRwt). Thanks to advances in imaging techniques and the possibility of achieving a non-
Pablo, Garcia-Pavia, Fernando, Domínguez, Esther, Gonzalez-Lopez   +2 more
openaire   +4 more sources

Transthyretin amyloid cardiomyopathy

The American Journal of the Medical Sciences, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure and arrhythmia. This differential diagnosis should particularly be considered in older patients with left ventricular hypertrophy (LVH) who are also suffering from heart failure with preserved ejection fraction (HFpEF) or aortic valve stenosis.
Giuseppe, Famularo, Guido, Ventroni
openaire   +4 more sources

Amyloid Cardiomyopathy

Heart, Lung and Circulation, 2020
Amyloid cardiomyopathy is emerging as an important and under-recognised cause of heart failure and cardiac arrhythmias, especially in older adults. This disorder is characterised by extracellular deposition of amyloid fibrils that form due to misfolding of secreted light chains (AL) or transthyretin protein (ATTR). In ATTR, amyloid aggregates typically
Nicole K. Bart, Liza Thomas, Dariusz Korczyk, John J. Atherton, Graeme J. Stewart, Diane Fatkin   +5 more
openaire   +5 more sources

Fulminant Amyloid Cardiomyopathy

Cardiology, 1993
Within a 3-month period, a 71-year-old man went from an asymptomatic, active existence to intractable heart failure and death. Widespread amyloid deposition was noted on the histologic examination of endomyocardial biopsy samples. The historical and laboratory features of this patient's rapidly devastating clinical course form the basis of this report.
B J, Donelan, D A, Orsinelli, R C, Patel, C V, Leier   +3 more
openaire   +2 more sources

Clinical management of amyloid cardiomyopathy

Heart Failure Reviews, 2021
Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical management of amyloid cardiomyopathy.
Morris M. Kim, Clinton M. Kolseth, Dayna Carlson, Ahmad Masri   +3 more
openaire   +2 more sources

Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.

Journal of the American College of Cardiology
BACKGROUND Acoramidis is a novel, high-affinity stabilizer that achieves ≥90% transthyretin (TTR) stabilization. The phase 3 study, ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), met its primary ...
M. Maurer, D. Judge, J. Gillmore, P. García-Pavía, Ahmad Masri, F. Cappelli, K. Alexander, N. Sarswat, Martha Grogan, A. Ambardekar, Anique Ducharme, S. Poulsen, Kaitlyn Lam, L. Obici, P. Soman, Satish Rao, J. Tamby, Adam Castaño, Jonathan C. Fox, Brian Adam, S. Chepyala, Bill Poland, Uma Sinha, Marianna Fontana   +23 more
semanticscholar   +1 more source

A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy

JACC CardioOncology
Background Tafamidis improved survival and decreased cardiovascular hospitalizations in the ATTR-ACT trial. Due to improved recognition and earlier diagnosis, the epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) is rapidly evolving ...
Ahmad Masri, Priyanka T Bhattacharya, Brent Medoff, Ain Ejaz, Miriam Elman, P. Chandrashekar, L. Ives, Alfonsina M Santos, S. Teruya, Yuanzi Zhao, Shuaiqi Huang, Xiaofeng Wang, Brett W. Sperry, Mathew S Maurer, P. Soman, M. Hanna   +15 more
semanticscholar   +1 more source

Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy

American Journal of Therapeutics, 2021
Background: Deposition of wild-type or mutant transthyretin (TTR) amyloid fibrils in the myocardium causes TTR amyloid cardiomyopathy (ATTR-CM). Targeted therapeutics for ATTR-CM include TTR stabilizers (tafamidis and diflunisal) and oligonucleotide drugs (revusiran, patisiran, and inotersen).
Courtney M, Campbell, Cyril Ayuk Mbeng Takem, Baiyee, Salem, Almaani, Naresh, Bumma, Nidhi, Sharma, Samantha, LoRusso, Elyse, Redder, Jordan, Bittengle, Katherine, Pfund, Miriam, Friemer, Matthew, Tong, Rami, Kahwash, Yvonne, Efebera, Samir, Parikh, Ajay, Vallakati   +14 more
openaire   +2 more sources

Echocardiographic Findings in Amyloid Cardiomyopathy

Southern Medical Journal, 1978
Echocardiographic manifestations of two patients with cardiac amyloidosis are presented. The findings consisted of increased thickness of the left ventricular posterior wall and interventricular septal wall, a normal to small left ventricular cavity, and pericardial effusion.
T D, Giles, J, León-Galindo, G E, Burch
openaire   +2 more sources

Newer Therapies for Amyloid Cardiomyopathy

Current Heart Failure Reports, 2016
The heart and the kidneys are the most commonly involved organs in systemic amyloidosis. Cardiac involvement is associated with an increased morbidity, treatment intolerance, and poorer overall survival. The most common types of amyloidosis that are associated with cardiac involvement include light chain (AL) amyloidosis and transthyretin (TTR ...
Rajshekhar, Chakraborty, Eli, Muchtar, Morie A, Gertz   +2 more
openaire   +2 more sources